...
首页> 外文期刊>Archiv der Pharmazie >Design, Synthesis, and Molecular Docking Studies of 2-(Furan-2-yl)quinazolin-4-one Derivatives as Potential Antiproliferative Agents
【24h】

Design, Synthesis, and Molecular Docking Studies of 2-(Furan-2-yl)quinazolin-4-one Derivatives as Potential Antiproliferative Agents

机译:2-(呋喃-2-基)喹唑啉-4-酮衍生物作为潜在抗增殖剂的设计,合成和分子对接研究

获取原文
获取原文并翻译 | 示例
           

摘要

Fifteen new derivatives of quinazolin-4-one bearing the 2-furyl moiety at position 2 and a substituted phenyl moiety at position 3 were designed and synthesized to be evaluated as cytotoxic agents. Their chemical structures were confirmed by spectral and elemental analysis; cytotoxic activity evaluation was performed against HEPG2, HCT116, and MCF7 cancer cell lines using the sulforhodamine-B assay. All the tested compounds except 6a showed high potency against the HEPG2 cancer cell line (IC50 8-101 nM/mL); 11 compounds out of 15 proved to be potent against HCT116 cells (IC50 3-49nM/mL), also 11 of the tested compounds showed high potency against MCF7 cells with IC50 values ranging from 7 to 63nM/mL. The rest of the tested compounds showed IC50 values of more than 100nM/mL. Compounds 3e and 4d are the most active compounds against HEPG2 cells; in addition, 3e is the most active compound against MCF7 cells. Also, compounds 4a, 3a, and 3b are the most active compounds against HCT116 cells. Compounds 3a, 3b, 3e, 4a, and 4d were also evaluated for their inhibitory activity against the EGFR tyrosine kinase (EGFR-TK) and showed a percentage inhibitory activity ranging from 53 to 84%. The most potent EGFR-TK inhibitors, 3a (84%), 3b (75%), and 3e (60%), were docked into the ATP binding site of the EGFR to explore their binding mode and possible interactions.
机译:设计并合成了十五种新的喹唑啉-4-酮衍生物,其在2位带有2-呋喃基部分和在3位带有取代的苯基部分,被评估为细胞毒性剂。通过光谱和元素分析证实了它们的化学结构;使用磺基罗丹明B检测法对HEPG2,HCT116和MCF7癌细胞进行了细胞毒性活性评估。除6a外的所有受试化合物均对HEPG2癌细胞系表现出高效力(IC50 8-101 nM / mL)。 15种化合物中有11种被证明对HCT116细胞有效(IC50为3-49nM / mL),其中11种化合物对MCF7细胞也具有高效力,IC50值为7至63nM / mL。其余测试化合物的IC50值均超过100nM / mL。化合物3e和4d是对HEPG2细胞最具活性的化合物;此外,3e是对抗MCF7细胞最具活性的化合物。同样,化合物4a,3a和3b是对HCT116细胞最具活性的化合物。还评估了化合物3a,3b,3e,4a和4d对EGFR酪氨酸激酶(EGFR-TK)的抑制活性,并显示了53%至84%的抑制活性百分比。将最有效的EGFR-TK抑制剂3a(84%),3b(75%)和3e(60%)对接至EGFR的ATP结合位点,以探索其结合模式和可能的相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号